Comparative effectiveness of six to eight hour infusions of phosphate, sulfate, and hydrocortisone was studied in 22 hypercalcemic patients with neoplastic disease. Mean maximum reduction in serum calcium level with phosphate was dose dependent: 25 millimols, 1.1 mg/100 ml; 50 millimols, 2.44 mg/100 ml; 75 millimols, 4.13 mg/ 100 ml; and 100 millimols, 6.08 mg/100 ml. The reduction was also directly related to the rise in serum phosphate level. Sulfate infusion (38.9 gm) caused an average maximum decrease of serum calcium of 1.87 mg/100 ml. Hydrocortisone (200 mg) produced minor inconsistent changes in serum calcium and phosphate levels. Infusions of phosphate caused reduction in urinary calcium and rise in phosphate level. Both sulfate and hydrocortisone infusions resulted in rises in urinary calcium and urinary phosphate. These studies demonstrate the superiority of phosphate in treatment of hypercalcemia and suggest guidelines for dose selection.
Fulmer DH, Dimich AB, Rothschild EO, Myers WPL. Treatment of Hypercalcemia: Comparison of Intravenously Administered Phosphate, Sulfate, and Hydrocortisone. Arch Intern Med. 1972;129(6):923–930. doi:10.1001/archinte.1972.00320060071008
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: